OncoSec Medical Inc (ONCSQ)

[hschlauch]

Titan, other than the response and safety data presented in the tavo/pembro combination p2b poster, there is something else that really caught my eye. The nonresponders to the combination are seeing significant increases in FOXP3-positive Treg cells.

Why is this important? FOXP3-positive Tregs promote CTLA-4 expression. This expression inhibits immune responses, because CTLA-4 outcompetes CD28 for ligands on antigen presenting cells.

Adding an encoded anti-CTLA-4 agent in a PIIM construct will more than likely lead to complete responses across the board. I would value a multigene construct with encoded anti-CTLA-4 well into the billions of dollars.